- Clinical Trials
AUSTIN, TX, April 26, 2012
A clinical trial has demonstrated that Oncoprex® (TUSC2 nanoparticles) can be safely administered in advanced lung cancer patients to halt cancer or shrink primary and metastatic tumors in some patients. The clinical trial results were published April 26, 2012 in a paper entitled, “Phase I Clinical Trial of Systemically Administered …
CHICAGO, IL and AUSTIN, TX, April 2, 2012 – Genprex, Inc.
New data demonstrating the anti-cancer activities of Oncoprex® were presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago IL. The study, “Synergistic antitumor activity of AKT inhibitor MK2206 and FUS1 nanoparticles in LKB1 mutant NSCLC” (Meng J, Lara-Guerra H, Ji L, Roth JA) is authored by a team of investigators from The University of Texas MD Anderson Cancer Center. …